Schürner, Anna M.
Manzini, Giulia
Bueter, Marco
Schadde, Erik
Beck-Schimmer, Beatrice
Schläpfer, Martin http://orcid.org/0000-0003-4288-7124
Funding for this research was provided by:
UniversitätsSpital Zürich (n.a.)
Article History
Received: 18 May 2018
Accepted: 29 November 2018
First Online: 13 December 2018
Ethics approval and consent to participate
: This retrospective data analysis was approved by the local ethics committee in Zurich: Kantonale Ethikkomission Zurich, Switzerland, Chaired by Peter Meier-Abt, KEK-ZH-No. 2015–0260; 14th of July, 2015. For retrospective data analyses, written and informed consent was not requested according the decision of the local ethics committee – documented living will in patient files (e.g. of not analysing patient data) had to be followed.
: Not applicable.
: AMS, GM, ES and MB: none.BBS: BBS received a grant from Baxter AG, not related to this work. BBS was a participant of an Advisory Board Meeting of Baxter AG, not related to this topic. BBS chaired a session (Satellite Symposium on ‘General Anaesthesia and its effect on organ function – What do we know?) at Euroanaesthesia 2013, organized by Baxter AG. BBS is councillor of the Swiss National Science Foundation (SNSF). BBS is associate editor of ‘Anesthesiology’. BBS received a speaker’s fee from Abbvie, Switzerland (Pro/cons of volatile anaesthetics) for a Grand Round talk in a Swiss Hospital. BBS has a patent 04/10/14–20,140,100,278: Injectable formulation for treatment and protection of patients having an inflammatory reaction or an ischemia-reperfusion event; M. Urner, L.K. Limbach, I.K. Herrmann, W.J. Stark, B. Beck Schimmer, applied as PCT (internationally), July 2009.MS: MS has received travel support from Baxter AG.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.